|
Clinical trial underway for
new monoclonal
antibody daclizumab
Click
here to view or print this bulletin in its
original format.
Medical Update Memo
February 24, 2006
An international multi-centre clinical trial
is underway to test the safety and effectiveness of daclizumab
compared with inactive placebo. Investigators – including
study sites in Canada – are enrolling 270 participants
who meet the study criteria, which includes currently taking
one of the beta interferon therapies.
About daclizumab: This agent is a laboratory-created
monoclonal antibody that blocks the activity of a key immune
activator in MS. A small study involving 19 people with relapsing-remitting
or secondary-progressive MS conducted by Dr. John Rose and
colleagues at the University of Utah found the therapy resulted
in stability (nine participants) or improvement (10).
Clinical trial criteria: To be eligible
for the study, participants must be 18-55 years old, have definite
MS, be taking one of the beta interferon therapies and have
experienced a relapse or MRI-detected disease activity within
nine months prior to screening.
For more information, call the study enrolment
centre at 1 800 772-0482 (English only) or go to the study
website: www.choicestudy.com (English only)
ASK MS Information System Code:
1.4.1.12.2w
National Research Department
National Communications & Government Relations Department
Disclaimer
The Multiple Sclerosis Society of Canada is an independent,
voluntary health agency and does not approve, endorse or
recommend any specific product or therapy but provides information
to assist individuals in making their own decisions.
|
